Skip to main content
. Author manuscript; available in PMC: 2011 Jun 1.
Published in final edited form as: Pharm Res. 2010 Jan 27;27(6):989–998. doi: 10.1007/s11095-010-0051-8

Fig. 3.

Fig. 3

Polo box domain inhibitors. These compounds have been shown to bind to the Polo box domains of Plk1. This binding alters Plk1 localization and binding to Plk1 targets.